rus
Issue #1/2018
M.Tarasov, I.Chicherin, I.Pogorelsky
Selective effect of nanostructured preparations on pathogenic bacteria
Selective effect of nanostructured preparations on pathogenic bacteria
Complex multidisciplinary research on the interaction of nanostructured preparations with intestinal microbiota and intestinal infections was recognized by the International academy of authors of scientific discoveries and inventions by scientific discovery with priority on the date of filing the application No.A-652 of December 27, 2016.
Теги: intestinal infections intestinal microbiota nano-therapy кишечная микробиота кишечные инфекции нанотерапия
The effectiveness of the prevention of infectious diseases, including acute intestinal infections, largely depends on the sensitivity of infectious agents to antibacterial drugs [1]. At the same time, the general outlook for the development of the world, and hence the domestic markets for antibiotics and chemotherapeutic drugs, is assessed negatively. It is important to note that unfavorable trends in the development of the market for antibiotics and chemotherapeutic drugs are combined with information on side effects and complications from their use [1, 2]. The unsystematic and uncontrolled use of antibacterial drugs adversely affects the human body, which manifests itself in toxic reactions, lesions of the kidney and liver parenchyma, damage to the peripheral nervous system and hematopoiesis, allergic reactions, immunodepressive state, antibiotic-associated dysbiosis.
In the United States, in the framework of the Rapidly Adaptable Nanotherapeutics project, it is planned to develop a new class of antibacterial and antiviral drugs consisting of nanoparticles as a "carrier" and small interfering RNAs (miRNA). Such a genetic construction after introduction into the body will be able to find the cells where the infection develops, and to stop the infectious process.
In Russia, NanoTechProm has developed a technology for therapeutic nanostructured drugs whose high therapeutic activity is caused by experimentally fixed effects of changes in the structure of nano-preparations due to activation directly in the lesion site [1, 2]. For the organization of production of medical nanostructured preparations, a plant was built. Experimental batches of preparations of Sky-force, Pentacycline, Rifomast, Endosuper, which showed high efficiency in experimental and clinical trials on tens of thousands of farm animals (birds, cattle), were manufactured and tested [3].
In the course of experimental and clinical studies of nanostructured preparations, a previously unknown effect of selective action on pathogenic bacteria and the absence of bactericidal action on the intestinal microbiota of the intestine, which fulfills the most important functions in the living body and ultimately determines the health of the organism or its disease, were discovered.
Nanostructural preparations are not antibiotics and do not contain residual amounts of antibiotics, they are not addictive and the population of antibiotic-resistant strains of infectious diseases of the intestine is not formed. Nanostructural drugs are effective in short courses of treatment.
The International academy of authors of scientific discoveries and inventions has recognized the presented materials as a discovery entitled "The phenomenon of selectivity of the effect of nanostructured chemotherapeutic drugs with a tunable nanostructure and a changeable topology of the surface on intestinal pathogens" with a priority on the date of filing application No.A-652 of December 27, 2016.
The discovery refers to medicine and veterinary medicine, namely, to clinical and experimental microbiology, and can be used to create new means of treatment and prevention of systemic bacterial intestinal infections and dysbiosis, while maintaining the qualitative and quantitative composition of the intestinal microbiota. ■
In the United States, in the framework of the Rapidly Adaptable Nanotherapeutics project, it is planned to develop a new class of antibacterial and antiviral drugs consisting of nanoparticles as a "carrier" and small interfering RNAs (miRNA). Such a genetic construction after introduction into the body will be able to find the cells where the infection develops, and to stop the infectious process.
In Russia, NanoTechProm has developed a technology for therapeutic nanostructured drugs whose high therapeutic activity is caused by experimentally fixed effects of changes in the structure of nano-preparations due to activation directly in the lesion site [1, 2]. For the organization of production of medical nanostructured preparations, a plant was built. Experimental batches of preparations of Sky-force, Pentacycline, Rifomast, Endosuper, which showed high efficiency in experimental and clinical trials on tens of thousands of farm animals (birds, cattle), were manufactured and tested [3].
In the course of experimental and clinical studies of nanostructured preparations, a previously unknown effect of selective action on pathogenic bacteria and the absence of bactericidal action on the intestinal microbiota of the intestine, which fulfills the most important functions in the living body and ultimately determines the health of the organism or its disease, were discovered.
Nanostructural preparations are not antibiotics and do not contain residual amounts of antibiotics, they are not addictive and the population of antibiotic-resistant strains of infectious diseases of the intestine is not formed. Nanostructural drugs are effective in short courses of treatment.
The International academy of authors of scientific discoveries and inventions has recognized the presented materials as a discovery entitled "The phenomenon of selectivity of the effect of nanostructured chemotherapeutic drugs with a tunable nanostructure and a changeable topology of the surface on intestinal pathogens" with a priority on the date of filing application No.A-652 of December 27, 2016.
The discovery refers to medicine and veterinary medicine, namely, to clinical and experimental microbiology, and can be used to create new means of treatment and prevention of systemic bacterial intestinal infections and dysbiosis, while maintaining the qualitative and quantitative composition of the intestinal microbiota. ■
Readers feedback
